JP2004521124A5 - - Google Patents

Download PDF

Info

Publication number
JP2004521124A5
JP2004521124A5 JP2002563891A JP2002563891A JP2004521124A5 JP 2004521124 A5 JP2004521124 A5 JP 2004521124A5 JP 2002563891 A JP2002563891 A JP 2002563891A JP 2002563891 A JP2002563891 A JP 2002563891A JP 2004521124 A5 JP2004521124 A5 JP 2004521124A5
Authority
JP
Japan
Prior art keywords
alkyl
group
substituted
ring
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002563891A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004521124A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/004680 external-priority patent/WO2002064094A2/en
Publication of JP2004521124A publication Critical patent/JP2004521124A/ja
Publication of JP2004521124A5 publication Critical patent/JP2004521124A5/ja
Pending legal-status Critical Current

Links

JP2002563891A 2001-02-09 2002-02-05 糖尿病および脂質障害用の２−アリールオキシ−２−アリールアルカン酸類 Pending JP2004521124A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26780901P 2001-02-09 2001-02-09
PCT/US2002/004680 WO2002064094A2 (en) 2001-02-09 2002-02-05 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders

Publications (2)

Publication Number Publication Date
JP2004521124A JP2004521124A (ja) 2004-07-15
JP2004521124A5 true JP2004521124A5 (https=) 2009-01-15

Family

ID=23020208

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002563891A Pending JP2004521124A (ja) 2001-02-09 2002-02-05 糖尿病および脂質障害用の２−アリールオキシ−２−アリールアルカン酸類

Country Status (6)

Country Link
US (2) US7091230B2 (https=)
EP (1) EP1366012A4 (https=)
JP (1) JP2004521124A (https=)
AU (1) AU2002251978B2 (https=)
CA (1) CA2437118A1 (https=)
WO (1) WO2002064094A2 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
PE20020323A1 (es) * 2000-08-22 2002-06-13 Novartis Ag COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
IL156445A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
SK9502003A3 (en) * 2001-01-26 2003-12-02 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
PT1385548E (pt) * 2001-01-26 2007-08-24 Schering Corp Combinações de um inibidor ou de inibidores de absorção de esteróis com agente (s) para o tratamento de doenças vasculares
WO2002058733A2 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
WO2002058685A2 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
WO2003088962A1 (en) * 2002-04-16 2003-10-30 Merck & Co., Inc. Combination therapy using a ppar alpha/gamma agonist
NZ537301A (en) * 2002-06-07 2006-06-30 Cortical Pty Ltd Therapeutic molecules and methods-1
FR2845602B1 (fr) * 2002-10-11 2005-07-08 Servier Lab Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
FR2845601B1 (fr) * 2002-10-11 2005-07-08 Servier Lab Nouvelle association entre un compose heterocyclique et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
ES2311117T3 (es) * 2002-12-10 2009-02-01 Novartis Ag Combinacion de un inhibidor de dpp-iv y un compuesto ppar-alfa.
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517572C (en) 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
BRPI0409447A (pt) * 2003-04-14 2006-04-18 Inst For Pharm Discovery Inc ácidos fenilalcanóicos substituìdos
CN1812977A (zh) 2003-04-30 2006-08-02 药物研发有限责任公司 取代羧酸
JPWO2004106542A1 (ja) * 2003-05-29 2006-07-20 三共株式会社 インスリン抵抗性改善剤及びそのスクリーニング方法
US7132426B2 (en) 2003-07-14 2006-11-07 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
KR100706600B1 (ko) * 2004-11-25 2007-04-12 주식회사 엘지생명과학 ＰＰＡＲ ｇａｍｍａ와 ＰＰＡＲ ａｌｐｈａ의 활성을항진시키는 신규 화합물, 그것의 제조방법, 및 그것을함유한 약제 조성물
KR20060058632A (ko) * 2004-11-25 2006-05-30 주식회사 엘지생명과학 ＰＰＡＲ ｇａｍｍａ와 ＰＰＡＲ ａｌｐｈａ의 활성을항진시키는 신규 화합물, 그것의 제조방법, 및 그것을함유한 약제 조성물
CN101128441A (zh) * 2005-03-04 2008-02-20 默克公司 具有抗糖尿病活性的稠合芳香化合物
JP2008538351A (ja) * 2005-03-21 2008-10-23 メタボレックス インコーポレーティッド 癌を含むＰＰＡＲγ反応性疾患の処置または予防における浮腫を回避するための方法
US20070161006A1 (en) * 2006-01-10 2007-07-12 Vita Genomics, Inc. Single nucleotide polymorphisms in protein-tyrosine phosphatase receptor-type delta for the diagnosis of susceptibility to infection and asthma
US9308198B2 (en) 2006-09-08 2016-04-12 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
US8338458B2 (en) 2007-05-07 2012-12-25 Merck Sharp & Dohme Corp. Method of treatment using fused aromatic compounds having anti-diabetic activity
EP2298729A4 (en) * 2008-06-03 2012-12-19 Kaneka Corp PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINO ACID DERIVATIVE
JP5374085B2 (ja) * 2008-07-22 2013-12-25 株式会社 資生堂 ４−アルキルレゾルシノールおよび４−アルケニルレゾルシノールの製造方法
CN101811968B (zh) * 2010-02-09 2014-07-30 深圳市有为化学技术有限公司 多官能团化苯甲酰甲酸羟基酮酯类化合物及含有该类化合物的光引发剂
PH12013500547A1 (en) 2010-09-22 2013-06-10 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013071077A1 (en) 2011-11-09 2013-05-16 Cornell University The use of pan-ppar agonists for prevention and treatment of huntington's disease and tauopathies
EP2975031A4 (en) 2013-03-14 2017-04-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
MX386419B (es) 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
EP3939965A1 (en) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3378582A (en) * 1964-03-20 1968-04-16 Merck & Co Inc (alpha-phenoxy)-and (alpha-phenylthio)-omegaphenyl-alkanoic acids
US3517050A (en) * 1966-10-03 1970-06-23 Merck & Co Inc Ester and amide derivative of (3-trifluoromethylphenoxy) (4 - halophenyl)acetic acid
US3787423A (en) * 1972-03-08 1974-01-22 Merck & Co Inc Beta-picolyloxy ester of(3-trifluoromethylphenoxy)(4-chlorophenyl)acetic acid and derivatives
US3953465A (en) * 1972-04-11 1976-04-27 Merck & Co., Inc. 2-[α-(3-Trifluoromethylphenoxyl)-4-chlorobenzyl]oxazole and methods for preparing the same
US3816446A (en) * 1972-04-11 1974-06-11 Merck & Co Inc (alpha-(3-trifluoromethylphenoxy)-4-chlorobenzyl)heterocycles
ZA765075B (en) * 1975-09-25 1977-08-31 American Cyanamid Co Hypolipemic compounds and method of treatment
US4168385A (en) * 1975-09-25 1979-09-18 American Cyanamid Company Hypolipemic phenylacetic acid derivatives
US4125732A (en) * 1977-05-06 1978-11-14 American Cyanamid Company 2-Aryloxy-2-(phenoxyalkoxy)phenyl acetic acid and esters
US4820715A (en) * 1984-06-28 1989-04-11 Bristol-Myers Company Anti-emetic quinuclidinyl benzamides
US4748272A (en) * 1986-08-01 1988-05-31 Rorer Pharmaceutical Corp. Phenoxyphenylacetates for use as potential modulators of arichidonic acid pathways
US4920132A (en) * 1987-11-03 1990-04-24 Rorer Pharmaceutical Corp. Quinoline derivatives and use thereof as antagonists of leukotriene D4
US5183810A (en) * 1990-02-13 1993-02-02 Merck & Co., Inc. Imidazole angiotensin II antagonists incorporating a substituted benzyl element
US5240938A (en) * 1991-02-13 1993-08-31 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring
US5177095A (en) * 1990-02-13 1993-01-05 Merck & Co., Inc. Triazole angiotensin II antagonists incorporating a substituted benzyl element
US5449682A (en) * 1990-02-13 1995-09-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted benzyl element
US5264439A (en) * 1990-02-13 1993-11-23 Merck & Co., Inc. Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element
DE4123341A1 (de) * 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5374638A (en) * 1993-03-19 1994-12-20 Merck & Co., Inc. Six membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives used to treat asthma
EP0617001B1 (en) * 1993-03-19 2000-01-26 Merck & Co. Inc. Phenoxyphenylacetic acid derivatives
US5401745A (en) * 1993-03-19 1995-03-28 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5767310A (en) * 1993-03-19 1998-06-16 Merck & Co., Inc. Phenoxyphenylacetic acid derivatives
US5334598A (en) * 1993-03-19 1994-08-02 Merck & Co., Inc. Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
US5420133A (en) * 1993-03-19 1995-05-30 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5565485A (en) * 1993-03-19 1996-10-15 Merck & Co., Inc. Biphenyl compounds useful or endothelin antagonists
US5391566A (en) * 1993-07-20 1995-02-21 Merck & Co., Inc. Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
AU3642795A (en) 1994-09-27 1996-04-19 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
US5596124A (en) * 1994-12-09 1997-01-21 American Cyanamid Company Method for safening herbicides in cereal crops using 5-aryloxy-1,2-(disubstituted)benzene compounds
DE19530032A1 (de) * 1995-08-16 1997-02-20 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
JP2000501737A (ja) 1995-12-12 2000-02-15 メルク エンド カンパニー インコーポレーテッド 立体選択的方法
US5688974A (en) * 1995-12-12 1997-11-18 Merck & Co., Inc. Process for the preparation of an endothelin antagonist
EP0873334A1 (en) 1995-12-12 1998-10-28 Merck & Co., Inc. (a New Jersey corp.) Process for the preparation of an endothelin antagonist
US5708186A (en) * 1995-12-12 1998-01-13 Merck & Co Inc Stereoselective process
EP0888278B1 (en) * 1996-02-02 2003-07-23 Merck & Co., Inc. Antidiabetic agents
DE69720429T9 (de) * 1996-02-02 2004-09-23 Merck & Co., Inc. Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
DE19614204A1 (de) * 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2291026A1 (en) 1997-06-05 1998-12-10 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
US6110963A (en) * 1998-05-12 2000-08-29 American Home Products Corporation Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
JP2002514638A (ja) 1998-05-12 2002-05-21 アメリカン・ホーム・プロダクツ・コーポレイション インスリン抵抗性および高血糖症の治療に有用な１１−アリール−ベンゾ［ｂ］ナフト［２，３−ｄ］フラン類および１１−アリール−ベンゾ［ｂ］ナフト［２，３−ｄ］チオフェン類
AU3791799A (en) 1998-05-12 1999-11-29 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6624194B1 (en) 1999-06-04 2003-09-23 Metabolex, Inc. Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
AU784722B2 (en) * 2000-02-18 2006-06-01 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders

Similar Documents

Publication Publication Date Title
JP2004521124A5 (https=)
JP2006522035A5 (https=)
JP2009515872A5 (https=)
JP2005522480A5 (https=)
JP2008500997A5 (https=)
JP2006526608A5 (https=)
RU95118736A (ru) Промежуточное соединение для получения гетероциклических соединений, обладающих антидиабетической активностью
JP2010535722A5 (https=)
JP2004083852A5 (https=)
JP2013542213A5 (https=)
JP2002502874A5 (https=)
EA200000731A1 (ru) Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
EP1724258A4 (en) HETEROARYLPHENYLHARNSTOFFDERIVAT
DK0539117T3 (da) Forbindelser, der er nyttige som leukotrien-antagonister
FI903939A0 (fi) Benzopyranfoereningar, foerfaranden foer deras framstaellning och farmaceutiska kompositioner.
JP2006509842A5 (https=)
BRPI0409469A (pt) compostos para o tratamento de distúrbios metabólicos
JP2005517643A5 (https=)
ATE271045T1 (de) Sauerstoffhaltige heterocyclische verbindungen
JP2005536519A5 (https=)
JP2010535706A5 (https=)
JP2006523698A5 (https=)
SI9210092B (en) N-phenylcarbamate compound, procedure for its preparation and biocidal composition for pest control
JP2005503435A5 (https=)
JP2005526773A5 (https=)